Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 19/20 | 1.00 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.67 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044839 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL7077754 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL1126828 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2236412 | 0.80 | CYP11B1 (0.67) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL1024261 | 0.80 | CYP11B1 (0.84) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL707075 | 0.79 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.78 | CYP11B1 (0.81) | CYP11B1CYP11B2CYP19A1CYP2A6CYP2B6 | |
| SCHEMBL2730687 | 0.76 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL2729398 | 0.75 | CYP11B1 (1.00) | CYP11B1CYP11B2 | |
| SCHEMBL2731776 | 0.75 | CYP11B1 (1.00) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014145040-A1 | SUBSTITUTED ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-20250214978-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506345-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-12 | — | — | EP | disclosed |
| CN-116891464-A | AT2R agonist | 武汉人福创新药物研发中心有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023193733-A1 | AT2R AGONIST | 武汉人福创新药物研发中心有限公司 | 2023-10-12 | — | — | WO | disclosed |
| WO-2023274257-A1 | IMIDAZOLE COMPOUND, AND INTERMEDIATE AND APPLICATION THEREOF | 诸葛国琴 | 2023-01-05 | — | — | WO | disclosed |
| EP-3935944-A1 | COMPOUNDS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES | University Of Southern California, USC Stevens (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-2967049-B1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR THE TREATMENT OF ANGIOTENSIN-RELATED DISEASES | UNIV SOUTHERN CALIFORNIA (US) | 2020-09-02 | — | — | EP | disclosed |
| US-10301298-B2 | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180030042-A1 | Methods, Compounds, and Compositions for the Treatment of Angiotensin-Related Diseases | UNIVERSITY OF SOUTHERN CALIFORNIA | 2018-02-01 | — | — | US | disclosed |
| US-9732074-B2 | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-08-15 | — | — | US | disclosed |
| US-9394290-B2 | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases | UNIVERSITAET DES SAARLANDES CAMPUS SAARBRUECKEN (DE) | 2016-07-19 | — | — | US | disclosed |
| US-20160016946-A1 | Methods, Compounds, and Compositions for the Treatment of Angiotensin-Related Diseases | UNIVERSITY OF SOUTHERN CALIFORNIA | 2016-01-21 | — | — | US | disclosed |
| EP-2967049-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR THE TREATMENT OF ANGIOTENSIN-RELATED DISEASES | University Of Southern California (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145331-A1 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR THE TREATMENT OF ANGIOTENSIN-RELATED DISEASES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140155407-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | UNIVERSITAET DES SAARLANDES (DE) | 2014-06-05 | — | — | US | disclosed |
| EP-2630136-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | Universität des Saarlandes (DE) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012052540-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | UNIVERSITAET DES SAARLANDES (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301298-B2 | Methods, compounds, and compositions for the treatment of angiotensin-related diseases | AGT, ACE, REN | CYP11B1 608/4885CYP11B2 676/4885CYP19A1 1954/4885 |
| US-20250214978-A1 | AT2R AGONIST | AGTR1, AGTR2, AVPR2 | CYP11B1 113/4885CYP11B2 88/4885CYP19A1 2203/4885 |
| US-20180030042-A1 | Methods, Compounds, and Compositions for the Treatment of Angiotensin-Related Diseases | AGT, ACE, REN | CYP11B1 608/4885CYP11B2 676/4885CYP19A1 1954/4885 |
| US-20160016946-A1 | Methods, Compounds, and Compositions for the Treatment of Angiotensin-Related Diseases | ACE, AGT, REN | CYP11B1 951/4885CYP11B2 1057/4885CYP19A1 3147/4885 |
| US-20140155407-A1 | SELECTIVE CYP11B1 INHIBITORS FOR THE TREATMENT OF CORTISOL DEPENDENT DISEASES | HSD11B1, CYP11B1, HSD11B2 | CYP11B1 2/4885CYP11B2 4/4885CYP19A1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.